Meridian Bioscience (VIVO) Akcija Cena
Meridian Bioscience Cena
Pēdējos 19 gados Meridian Bioscience ieņēmumi auga par 8,9 % gadā un sasniedza 333,02 M USD. Peļņa uz akciju auga par 8,4 % gadā pēdējos 19 gados. Meridian Bioscience neto marža 12,7 % ir pieaugusi salīdzinājumā ar 11,1 % pirms dažiem gadiem. Pie šodienas cenas dividenžu ienesīgums ir aptuveni 7,81 %. Izmaksas koeficients ir ap 22 % no peļņas.
Meridian Bioscience akcijas cena
Iegūstiet šos datus caur Eulerpool API
100 000 pieprasījumu/mēn. bez maksas · bez kartes
Meridian Bioscience biznesa modelis un akciju analīze
Bieži uzdotie jautājumi par Meridian Bioscience akciju
The business model of Meridian Bioscience Inc revolves around manufacturing and distributing diagnostic products for the healthcare industry. With a focus on infectious disease testing, the company provides a range of products including molecular and immunoassay tests, as well as reagents and related equipment. Meridian Bioscience Inc aims to develop innovative solutions for quick and accurate diagnosis, helping healthcare professionals worldwide make informed decisions. Through its expertise and continual investment in research and development, the company strives to improve patient outcomes and contribute to the overall public health. Meridian Bioscience Inc's commitment to quality and customer satisfaction is evident in their comprehensive portfolio of diagnostic solutions.
Meridian Bioscience Inc is primarily active in the healthcare and life sciences industries.
The main competitors of Meridian Bioscience Inc in the market are companies like Thermo Fisher Scientific, BD (Becton, Dickinson and Company), Quidel Corporation, and Bio-Rad Laboratories. These companies operate in the healthcare and diagnostics industry, offering similar products and services. Meridian Bioscience Inc competes based on factors such as product quality, technological advancements, pricing strategy, and customer satisfaction. While Thermo Fisher Scientific is a well-established player in the market, Meridian Bioscience Inc continues to carve its niche through innovative solutions and a strong customer-centric approach.
Meridian Bioscience Inc is a leading life science company that develops and markets a broad range of innovative diagnostic products. Founded in 1976, the company has a rich history and a strong background in developing and commercializing diagnostic tests for various infectious diseases. Meridian Bioscience Inc has evolved over the years and has expanded its product portfolio to cater to the needs of laboratories, hospitals, and other healthcare providers worldwide. With a focus on quality, accuracy, and reliability, the company has garnered a reputation for delivering efficient and effective diagnostic solutions. Meridian Bioscience Inc remains committed to advancing healthcare and improving patient outcomes through its cutting-edge diagnostic technologies and dedication to innovation.
Meridian Bioscience Inc has achieved several significant milestones throughout its history. One notable accomplishment is the company's development and commercialization of innovative diagnostic test kits for various diseases and healthcare conditions. Furthermore, Meridian Bioscience Inc has consistently expanded its product portfolio, introducing novel technologies to improve healthcare outcomes. The company's dedication to research and development has led to the successful launch of multiple FDA-cleared and CE-marked diagnostic tests. Meridian Bioscience Inc's commitment to quality has enabled it to establish a strong presence in the global diagnostics market.
Meridian Bioscience Inc is primarily present in the United States.
Meridian Bioscience Inc represents a strong set of values and corporate philosophy. The company is committed to quality and innovation in the field of biotechnology. They strive to provide accurate and reliable diagnostic solutions to improve patient care. Meridian Bioscience Inc also prioritizes integrity and ethical conduct in all aspects of their business operations. With a focus on customer satisfaction, they aim to exceed expectations and deliver exceptional products and services. As an industry leader, Meridian Bioscience Inc continues to drive advancements in the healthcare sector through their dedication to excellence and integrity.
7 analītiķi pašlaik vērtē Meridian Bioscience akciju: 6 iesaka pirkt, 1 turēt un 0 pārdot.
Pēc pašreizējā kursa Meridian Bioscience akcija maksā 1,43 EUR (1,60 USD).
Meridian Bioscience akcija (VIVO) tiek kotēta 4 biržās, tostarp: NASDAQ (VIVO), London (0K0K.L), Frankfurt (MR4.F), München (MR4.MU).
Meridian Bioscience Inc is a global company specializing in the development, manufacture, and distribution of diagnostic and testing systems for the rapid and accurate identification of infectious diseases. The company was founded in 1976 and is headquartered in Cincinnati, Ohio. Meridian Bioscience operates several business segments, including diagnostics, OEM, and life science. In the diagnostics segment, the company offers a variety of products for the identification of infectious diseases, including tests for respiratory infections, gastroenteritis, STDs, and Zika virus. Meridian Bioscience's diagnostic products are used in clinical laboratories, hospitals, medical practices, and research laboratories worldwide. The OEM segment of Meridian Bioscience offers customized diagnostic products tailored to the specific requirements of OEM customers. This includes both raw materials and finished products that can be integrated into customers' diagnostic products. The OEM segment of Meridian Bioscience works closely with OEM customers to provide customized, cost-effective, and high-quality products. In the life science segment, Meridian Bioscience offers a wide range of products, including enzymes, antibodies, proteins, buffering solutions, and labeling reagents. These products are used in research and development, diagnostics, and industry. Meridian Bioscience has experienced strong growth in recent years, driven by the introduction of new products, expansion into new markets, and the acquisition of other companies. An example of this is the acquisition of the Bioline Group in 2018, a leading provider of molecular biology products used in research and diagnostics. Meridian Bioscience is committed to developing and manufacturing high-quality products that deliver fast and accurate results. The company works closely with customers and partners to develop innovative products that meet the needs of the healthcare industry. With its wide range of products and commitment to innovation and quality, Meridian Bioscience will continue to play an important role in the diagnostics industry.
Apgrozījums Meridian Bioscience pašlaik nevar tikt aprēķināts.
Peļņa Meridian Bioscience pašlaik nevar tikt aprēķināta.
P/E rādītājs Meridian Bioscience pašlaik nevar tikt aprēķināts.
P/S rādītājs Meridian Bioscience pašlaik nevar tikt aprēķināts.
Meridian Bioscience Eulerpool kvalitātes rādītājs ir 7/10.
Meridian Bioscience ISIN ir US5895841014. ISIN (International Securities Identification Number) ir pasaulē unikāls vērtspapīru identifikators.
Meridian Bioscience WKN ir 871583. WKN (Wertpapierkennnummer) ir sešciparu vācu vērtspapīru identifikācijas numurs.
Meridian Bioscience tikeris ir VIVO. Tikeris tiek izmantots Meridian Bioscience akciju tirdzniecībai biržā.
Meridian Bioscience akcija
Meridian Bioscience Salīdzināmo uzņēmumu grupa
Meridian Bioscience Biržas kods
Meridian Bioscience FIGI
Visi Meridian Bioscience fundamentālie rādītāji un padziļinātā analīze
Mūsu akciju analīze par Meridian Bioscience ietver svarīgus finanšu rādītājus, piemēram, apgrozījumu, peļņu, P/E rādītāju, P/S rādītāju, EBIT, kā arī informāciju par dividendēm. Turklāt mēs aplūkojam aspektus kā akcijas, tirgus kapitalizāciju, parādus, pašu kapitālu un saistības no Meridian Bioscience. Ja meklējat sīkāku informāciju par šīm tēmām, piedāvājam detalizētas analīzes mūsu apakšlapās: